Mr. Gary Thompson reports

M PHARMACEUTICAL INC. RECEIVES USPTO TRADEMARK PROTECTION FOR EXTRINSA FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION

M Pharmaceutical Inc. has recently received official U.S. Patent Office notice of allowance for the U.S. trademark of Extrinsa, the company's solution for female sexual dysfunction (FSD).

"We are excited to receive this additional USPTO trademark protection for our FSD product. At this critical stage in the development of Extrinsa, it is prudent and necessary to protect not only our technology, but our shareholders' investment dollars as well," said Gary Thompson, president and chief executive officer of M Pharmaceutical.

"Our staff at M Pharma is working closely with Camargo Pharmaceutical Services based in Cincinnati, Ohio, to strengthen and expedite the process to bring Extrinsa to market, benefiting millions of women suffering from female sexual dysfunction."

About Extrinsa

Unlike the other two drugs approved by the U.S. Food and Drug Administration to treat FSD, the company's topical drug product, Extrinsa, would focus on women with orgasm and arousal difficulties. Valeant's Addyi, recently acquired from Sprout Pharmaceuticals, is indicated only for HSDD (desire disorder) with a number of FDA-imposed prescription and marketing restrictions. Intrarosa, by Endoceutics, is indicated for dyspareunia (pain with intercourse) with certain prescribing restrictions. M Pharma's Extrinsa treatment is topical, local and non-systemic, with daily and on-demand use, while being non-hormonal and not a central nervous system drug. Based on these core attributes, the safety profiles of the API and excipients in the drug product, and the dosage and delivery form, the company anticipates Extrinsa to be extremely well tolerated and highly effective for many women suffering from FSD and has a great likelihood of ultimate approval by the FDA.

About M Pharmaceutical Inc.

M Pharmaceutical is a clinical-stage company developing innovative technologies for obesity, weight management, and female health and wellness. In addition to its recent acquisitions of C-103, a reformulation of orlistat from Chelatexx LLC and assets from 40J's LLC, the company is scheduled to launch its FDA-cleared fertility product branded as ToConceive in July of this year.

We seek Safe Harbor.